A Phase 3 interventional study of Tramadol Hydrochloride (HCL) plus Acetaminophen (JNS013) in Chronic Pain, sponsored by Janssen Pharmaceutical K.K.. Completed at 26 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-07-02.
Sponsored by Janssen Pharmaceutical K.K. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing tramadol in Chronic Pain — 2 open to participants now, 2 under way, none of them phase 3. Tramadol · Chronic Pain.
Among the 10 studies testing tramadol in Chronic Pain, this one is the 7th largest by enrollment, is one of 2 that started in 2008, is one of 7 in phase 3, and was the 6th registered.
3,228 studies on the registry are indexed under Chronic Pain; 729 are open to participants now.
Browse Chronic Pain studies →2 of the 10 studies testing tramadol in Chronic Pain are open now, in 2 countries. Recruiting first, the newest first:
The Cleveland Clinic · Sites in United States
Ages 18–65
University of Thessaly · Sites in Greece
Ages 18–80
By country, each count listing its studies:
Tramadol: first FDA approval 1995 (ULTRAM). What it is approved for, and how studies give it, is on its page →
Of the 487 Chronic Pain studies recruiting now, 240 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 8 · Phase 4 2
First in 2000; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 219 is above the median of 60 across 2,388 interventional studies indexed under Chronic Pain.
Median enrollment 283 across the 10 interventional studies. Of the 7 that completed or were terminated, 2 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 10 have an industry lead sponsor. The 5 most frequent:
This study is registered under Janssen Pharmaceutical K.K., one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Pharmaceutical K.K. is the lead sponsor of 126 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 7 (50%) have results posted.
22 studies in Chronic Pain by Johnson & Johnson: none open now, none under way, none of them phase 3. Of 22 finished, 8 (36%) have results posted.
Among the 22 studies in Chronic Pain by Johnson & Johnson, this one is the 8th largest by enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2008, is one of 11 in phase 3, and was the 8th registered.
Johnson & Johnson’s Chronic Pain studies by the year they started, since 1996.
1 of the studies testing tramadol in Chronic Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06373978The Cleveland ClinicNonNarcotic Pain Control in Percutaneous Needle Tenotomy of Elbow | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing tramadol in Chronic Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 22 in Chronic Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of tramadol hydrochloride plus acetaminophen (JNS013) with long term administration in participants with chronic pain.
This is an open-label (both physician and participant know the name of the study drug), non-randomized, multicenter (when more than one hospital or medical school team work on a medical research study) and long-term efficacy and safety study of JNS013 (combination of tramadol hydrochloride (TRAM) with acetaminophen [APAP]) in participants with chronic pain (aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain). This study consists of 4 periods; screening period: 1 week, treatment period I: 4 weeks, treatment period II: 48 weeks and follow-up period: 1 week. During Treatment Period I, restrictions on concomitant treatments will be established and the participants will be treated with one or two tablets of JNS013, four times daily for four weeks. During Treatment Period II, the participants will be treated for 48 weeks using the same dosing method and dose level for JNS013 as was used during Treatment Period I, permitting modifications to the concomitant drugs/therapies as during normal medical care. Throughout both Treatment Period I and Treatment Period II, the decision will be made to permit the participants to select to use either one or two tablets of JNS013 per dose according to the extent of the participant's pain and tolerability. The total duration of treatment period will be of 52 weeks. Efficacy will be assessed using change from baseline in Visual Analogue Scale for pain (VAS24) score at the pre-defined time point until Week 52. Participants safety will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tramadol Hydrochloride (HCL) plus Acetaminophen (JNS013)
Drug pages: Tramadol · Acetaminophen
Tramadol hydrochloride 37.5 milligram (mg) plus acetaminophen 325 mg (JNS013) one or two tablets will be given orally four times daily (maximum dose is 8 tablets per day) for 4 weeks during treatment period 1 (restrictions on concomitant treatments will be established) and for 48 weeks during treatment period 2 (permitting modifications to the concomitant drugs/therapies). The dosing interval will be of at least 4 hours.
Change From Baseline in Visual Analogue Scale (VAS24) Score at Week 4
Pain over the last 24 hours was assessed by using VAS score ranges from 0 millimeter (mm)=no pain to 100 mm=worst possible pain. An increase in score from baseline represented disease progression and decrease represented improvement.
Time frame: Baseline and Week 4
Change From Baseline in VAS24 Score at Week 52
Pain over the last 24 hours was assessed by using VAS score ranges from 0 mm=no pain to 100 mm=worst possible pain. An increase in score from baseline represented disease progression and decrease represented improvement.
Time frame: Baseline and Week 52
Number of Participants With Improvement From Baseline in VAS24 Score
Pain over the last 24 hours was assessed by using VAS score ranges from 0 mm=no pain to 100 mm=worst possible pain. An increase in score from baseline represented disease progression and decrease represented improvement.
Time frame: Week 4 and 52
Pain Intensity Difference (PID) at Week 4
PID is defined as the amount of change in the pain intensity at each evaluation time point (at 2 and 4 hours after the study drug dosing) from the baseline for each participant. Pain Intensity was evaluated on a 4-stage scale ranging from 3=severe pain to 0=no pain. PID ranges from -3 (the worst) to +3 (the most improved).
Time frame: Week 4
Pain Relief (PAR) Score at Week 4
Pain relief was evaluated based on a 5-stage scale from 4 (complete relief) to 0 (no relief). An increase in score represented improvement and decrease represented disease progression
Time frame: Week 4
Pain Relief Combined With Pain Intensity Difference (PRID) at Week 4
PRID was sum of the PID and PAR for each participant at each evaluation time point (2 hours after dosing, 4 hours after dosing). Pain Intensity was evaluated on a 4-stage scale ranges from 3=severe pain to 0=no pain and PID ranges from -3 (the worst) to +3 (the most improved). PAR ranges from 0 (no improved) to +4 (the most improved). PRID ranges from -3 (the worst) to +7 (the most improved).
Time frame: Week 4
Change From Baseline in Short Form-36 (SF-36) Score
SF-36 is a metric for general health and Quality of Life (QOL), consists of 8 sub-scale indices related to health and QOL (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, mental health). Each of the sub-scale scores ranged from 0 to 100, where higher values indicate a better health status or a better mental status.
Time frame: Baseline, Week 4 and 52
| Milestone | Tramadol Hydrochloride Plus Acetaminophen (JNS013) |
|---|---|
| Started | 219 |
| Treated | 190 |
| Completed | 97 |
| Not completed | 122 |
| Withdrew: Adverse event | 43 |
| Withdrew: Withdrawal by subject | 49 |
| Withdrew: Violation of eligibility criteria | 2 |
| Withdrew: Did not attend hospital appointments | 1 |
| Withdrew: Not eligible for treatment period i | 22 |
| Withdrew: Physician decision | 5 |
Pain over the last 24 hours was assessed by using VAS score ranges from 0 millimeter (mm)=no pain to 100 mm=worst possible pain. An increase in score from baseline represented disease progression and decrease represented improvement.
| millimeter | Tramadol Hydrochloride Plus Acetaminophen (JNS013) |
|---|---|
| Baseline | 65.80 ± 11.629 |
| Change at Week 4 | -22.28 ± 21.189 |
Pain over the last 24 hours was assessed by using VAS score ranges from 0 mm=no pain to 100 mm=worst possible pain. An increase in score from baseline represented disease progression and decrease represented improvement.
| millimeter | Tramadol Hydrochloride Plus Acetaminophen (JNS013) |
|---|---|
| Baseline | 65.80 ± 11.629 |
| Change at Week 52 | -36.54 ± 21.936 |
Pain over the last 24 hours was assessed by using VAS score ranges from 0 mm=no pain to 100 mm=worst possible pain. An increase in score from baseline represented disease progression and decrease represented improvement.
| participants | Tramadol Hydrochloride Plus Acetaminophen (JNS013) |
|---|---|
| Improvement of 30 percent or more at Week 4 | 76 |
| Improvement of 50 percent or more at Week 4 | 51 |
| Improvement of 30 percent or more at Week 52 | 110 |
| Improvement of 50 percent or more at Week 52 | 77 |
PID is defined as the amount of change in the pain intensity at each evaluation time point (at 2 and 4 hours after the study drug dosing) from the baseline for each participant. Pain Intensity was evaluated on a 4-stage scale ranging from 3=severe pain to 0=no pain. PID ranges from -3 (the worst) to +3 (the most improved).
| units on a scale | Tramadol Hydrochloride Plus Acetaminophen (JNS013) |
|---|---|
| 2 hours after dosing at Week 4 | 0.1 ± 0.35 |
| 4 hours after dosing at Week 4 | 0.1 ± 0.44 |
Pain relief was evaluated based on a 5-stage scale from 4 (complete relief) to 0 (no relief). An increase in score represented improvement and decrease represented disease progression
| units on a scale | Tramadol Hydrochloride Plus Acetaminophen (JNS013) |
|---|---|
| 2 hours after dosing at Week 4 | 1.3 ± 0.91 |
| 4 hours after dosing at Week 4 | 1.3 ± 0.99 |
PRID was sum of the PID and PAR for each participant at each evaluation time point (2 hours after dosing, 4 hours after dosing). Pain Intensity was evaluated on a 4-stage scale ranges from 3=severe pain to 0=no pain and PID ranges from -3 (the worst) to +3 (the most improved). PAR ranges from 0 (no improved) to +4 (the most improved). PRID ranges from -3 (the worst) to +7 (the most improved).
| units on scale | Tramadol Hydrochloride Plus Acetaminophen (JNS013) |
|---|---|
| 2 hours after dosing at Week 4 | 1.3 ± 1.06 |
| 4 hours after dosing at Week 4 | 1.4 ± 1.20 |
SF-36 is a metric for general health and Quality of Life (QOL), consists of 8 sub-scale indices related to health and QOL (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, mental health). Each of the sub-scale scores ranged from 0 to 100, where higher values indicate a better health status or a better mental status.
| units on a scale | Tramadol Hydrochloride Plus Acetaminophen (JNS013) |
|---|---|
| Physical functioning:Baseline | 33.7 ± 17.03 |
| Physical functioning:Change at Week 4 (n=150) | 2.9 ± 9.06 |
| Physical functioning:Change at Week 52 (n=96) | 4.1 ± 12.00 |
| Role-physical:Baseline | 35.0 ± 15.43 |
| Role-physical:Change at Week 4 (n=150) | 3.2 ± 11.51 |
| Role-physical:Change at Week 52 (n=96) | 6.0 ± 13.76 |
| Bodily pain:Baseline | 33.7 ± 6.70 |
| Bodily pain:Change at Week 4 (n=150) | 5.5 ± 7.12 |
| Bodily pain:Change at Week 52 (n=96) | 9.0 ± 8.74 |
| General health:Baseline | 42.1 ± 10.42 |
| General health:Change at Week 4 (n=150) | 1.5 ± 7.74 |
| General health:Change at Week 52 (n=96) | 3.9 ± 8.92 |
| Vitality:Baseline | 44.0 ± 9.82 |
| Vitality:Change at Week 4 (n=150) | 2.1 ± 8.37 |
| Vitality:Change at Week 52 (n=96) | 4.9 ± 9.38 |
| Social functioning:Baseline | 41.0 ± 13.61 |
| Social functioning:Change at Week 4 (n=150) | 2.7 ± 11.36 |
| Social functioning:Change at Week 52 (n=96) | 6.0 ± 11.57 |
| Role-emotional:Baseline | 39.4 ± 14.97 |
| Role-emotional:Change at Week 4 (n=150) | 2.6 ± 12.43 |
| Role-emotional:Change at Week 52 (n=96) | 5.2 ± 14.44 |
| Mental health:Baseline | 43.9 ± 11.50 |
| Mental health:Change at Week 4 (n=150) | 2.5 ± 8.73 |
| Mental health:Change at Week 52 (n=96) | 5.5 ± 10.11 |
Collected over From signing of informed consent until study completion (up to 54 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tramadol Hydrochloride Plus Acetaminophen (JNS013) | — | 24/190 (12.6%) | 189/190 (99.5%) |
| Event | Tramadol Hydrochloride Plus Acetaminophen (JNS013) |
|---|---|
| VomitingGastrointestinal disorders | 3/190 |
| Colon polypsGastrointestinal disorders | 2/190 |
| NauseaGastrointestinal disorders | 2/190 |
| BronchitisInfections and infestations | 1/190 |
| GastroenteritisInfections and infestations | 1/190 |
| PyelonephritisInfections and infestations | 1/190 |
| Cerebral infarctionNervous system disorders | 1/190 |
| Diabetic autonomic nerve neuropathyNervous system disorders | 1/190 |
| DizzinessNervous system disorders | 1/190 |
| Loss of consciousnessNervous system disorders | 1/190 |
| Event | Tramadol Hydrochloride Plus Acetaminophen (JNS013) |
|---|---|
| NauseaGastrointestinal disorders | 101/190 |
| ConstipationGastrointestinal disorders | 75/190 |
| VomitingGastrointestinal disorders | 68/190 |
| DizzinessNervous system disorders | 52/190 |
| NasopharyngitisInfections and infestations | 49/190 |
| SomnolenceNervous system disorders | 38/190 |
| HeadacheNervous system disorders | 28/190 |
| Weight decreasedInvestigations | 23/190 |
| Gamma-glutamyltransferase increasedInvestigations | 21/190 |
| Blood creatine phosphokinase increasedInvestigations | 19/190 |
| Age, Continuous(years) | Tramadol Hydrochloride Plus Acetaminophen (JNS013) |
|---|---|
| Mean | 64.3 ± 12.9 |
| Sex: Female, Male(Participants) | Tramadol Hydrochloride Plus Acetaminophen (JNS013) |
|---|---|
| Female | 106 |
| Male | 84 |
The record gives a start of May 2008, a primary completion of Oct 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2013, 3 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tramadol · Acetaminophen